Search Results for "block"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for block. Results 11 to 20 of 333 total matches.
Penpulimab (Anniko) for Nasopharyngeal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use
in combination ...
Penpulimab-kcqx (Anniko – Akeso Biopharma),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use
in combination with cisplatin or carboplatin plus
gemcitabine for first-line treatment of recurrent
or metastatic nonkeratinizing nasopharyngeal
carcinoma and for use as monotherapy for metastatic
disease in adults with disease progression on or after
platinum-based chemotherapy and at least one other
prior line of therapy. Penpulimab is the second immune
checkpoint inhibitor to be approved in the US for
treatment of nasopharyngeal carcinoma;...
Med Lett Drugs Ther. 2025 Jul 21;67(1733):e122-3 doi:10.58347/tml.2025.1733k | Show Introduction Hide Introduction
Prevention and Treatment of Sunburn
The Medical Letter on Drugs and Therapeutics • Jun 07, 2004 (Issue 1184)
block at least part of UVA II in addition to UVB.
SUN AVOIDANCE — Avoiding exposure to direct sunlight ...
Solar ultraviolet (UV) light capable of injuring the skin is classified by wavelength into UVA I (340-400 nm), UVA II (320-340 nm) and UVB (290-320 nm). UVB is responsible for most of the erythema of sunburn. UVA has been implicated in the development of phototoxicity and photoaging. The FDA permits sunscreen manufacturers to claim broad-spectrum protection if their products block at least part of UVA II in addition to UVB.
Click here to view the free full article.
Click here to view the free full article.
Retifanlimab (Zynyz) for Anal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
(Zynyz – Incyte), a programmed
death receptor-1 (PD-1)-blocking antibody, has been
approved by the FDA ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed
death receptor-1 (PD-1)-blocking antibody, has been
approved by the FDA for use in combination with
carboplatin and paclitaxel for first-line treatment of
unresectable locally recurrent or metastatic squamous
cell carcinoma of the anal canal (SCAC) and as
monotherapy in patients who had disease progression
or intolerance to platinum-based chemotherapy. The
drug received accelerated approval for treatment of
recurrent locally advanced or metastatic Merkel cell
carcinoma in 2023.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):e126-7 doi:10.58347/tml.2025.1733m | Show Introduction Hide Introduction
Maestro Rechargeable System for Weight Loss
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016 (Issue 1493)
electrical pulses to block vagus nerve
signals between the stomach and the brain. According ...
The FDA has approved the Maestro Rechargeable
System (EnteroMedics), a subcutaneously implanted
device, for use in adults who have not been able to lose
weight with a weight loss program within the past 5 years
and who have a body mass index (BMI) of 40 to 45, or a
BMI ≥35 and at least one obesity-related comorbidity.
Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
on dialysis. Tenapanor
was used as monotherapy in two of the trials (BLOCK,
PHREEDOM) and in addition ...
The FDA has approved the sodium/hydrogen
exchanger 3 (NHE3) inhibitor tenapanor (Xphozah –
Ardelyx) to reduce serum phosphorus in adults with
chronic kidney disease (CKD) on dialysis as add-on
therapy when phosphate binders are ineffective or
as monotherapy when phosphate binders cannot be
tolerated. Tenapanor is the first NHE3 inhibitor to be
approved in the US for hyperphosphatemia. It was
previously approved as Ibsrela to treat irritable bowel
syndrome with constipation (IBS-C).
Med Lett Drugs Ther. 2024 Mar 4;66(1697):38-9 doi:10.58347/tml.2024.1697b | Show Introduction Hide Introduction
Rocuronium - A New Neuromuscular Blocker
The Medical Letter on Drugs and Therapeutics • Aug 05, 1994 (Issue 928)
short-onset, intermediate-acting, nondepolarizing neuromuscular blocking drug, is now available ...
Rocuronium bromide (Zemuron - Organon), a new short-onset, intermediate-acting, nondepolarizing neuromuscular blocking drug, is now available in the USA for intravenous use. It is being promoted particularly for use in rapid endotracheal intubation.
Irbesartan for Hypertension
The Medical Letter on Drugs and Therapeutics • Jan 30, 1998 (Issue 1019)
, blocks the binding of angiotensin II to type 1 angiotensin II receptors. Angiotensin-converting-enzyme ...
Irbesartan (Avapro - Sanofi/Bristol-Myers Squibb) is the third angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension. Losartan (Cozaar) and valsartan (Diovan) were marketed earlier. Eprosartan (Teveten - SmithKline Beecham) has been approved by the FDA but not marketed.
Opdualag for Metastatic Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
-rmbw, a lymphocyte-activation gene-3
(LAG-3) blocking antibody — has been approved by
the FDA ...
Opdualag (BMS), a fixed-dose combination of two
immune checkpoint inhibitors — nivolumab (Opdivo),
a programmed death receptor-1 (PD-1) inhibitor, and
relatlimab-rmbw, a lymphocyte-activation gene-3
(LAG-3) blocking antibody — has been approved by
the FDA for treatment of unresectable or metastatic
melanoma in patients ≥12 years old. Relatlimab, which
is only available in combination with nivolumab, is
the first LAG-3 blocking antibody to become available
in the US. Immune checkpoint inhibitors, including
the anti-CTLA-4 antibody ipilimumab (Yervoy) and
the PD-1 inhibitors...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e19-20 doi:10.58347/tml.2023.1668g | Show Introduction Hide Introduction
Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use
in combination with cisplatin and gemcitabine for
first-line treatment of recurrent locally advanced or
metastatic nasopharyngeal carcinoma and for use as
monotherapy for treatment of recurrent unresectable
or metastatic nasopharyngeal carcinoma in adults
with disease progression on or after platinum-based
chemotherapy. It is the first immune checkpoint
inhibitor to be approved in the US for treatment of
nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7 doi:10.58347/tml.2024.1694e | Show Introduction Hide Introduction
Candesartan for Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 20, 1998 (Issue 1040)
— Candesartan, like irbesartan, losartan and valsartan, blocks the
binding of angiotensin II to type 1 ...
Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.